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A 39-year-old male presented with recurrent attacks of painless haematuria. The patient has a history of partial cystectomy for
bladder paraganglioma 10 years prior to the presentation. Imaging study and cystoscopic examination revealed a small anterior
wall bladder tumor. The histological examination of the lesion conﬁrmed that it was a urinary paraganglioma. Partial cystectomy
was performed to this recurrent lesion. This case report stresses the importance of life-long follow-up of these lesions.
1.Introduction
Extra-adrenal paragangliomas account for approximately
15% of all pheochromocytomas. It arises from chromaﬃn
cells of the paraganglionic system, and is located anywhere
from the bladder to the base of the skull in association with
the sympathetic chain [1].
In the urinary tract, paraganglia can persist around and
within the bladder wall as well as along the ureter. Bladder
paraganglioma constitutes less than 0.06% of all bladder
tumors and less than 1% of pheochromocytoma [2]. The
common presenting symptoms include paroxysmal hyper-
tension, haematuria, postmicturition syncope, headache,
sweating, and palpitation.
Surgical removal, either through partial cystectomy or
transurethralresection,isstillthegoldstandardoftreatment.
The current case report stresses the importance of the life-
long regular follow-up after the surgical management to
detect possible remote recurrence.
2.CaseReport
A 39-year-old male presented with recurrent attacks of
gross painless haematuria for 5 months. The patient has
a history of partial cystectomy for paraganglioma 10 years
prior to the presentation. The pathological report stated that
the surgical margin was negative. The urine catecholamine
level postresection was normal. He was followed for one
year postoperatively with cystoscopic examination without
any sign of recurrence. The patient does not have similar
history in the family. Regarding his second presentation, the
patient had no attacks of headache, sweating, palpitation,
anxiety, or postmicturition syncope. His blood pressure was
within normal range. Urine analysis revealed red blood
cells in large quantity. Plasma metanephrines and urine
vanillylmandelic acid (VMA) levels were within normal
limits. Abdominal CT scan showed a 3×2cm oval-shaped
homogenous anterior bladder wall mass. The mass showed
intense uniform enhancement with contrast study. There
was no associated lymphadenopathy or invasion to the
surrounding pelvic structures (Figure 1).
Because of the history of bladder paraganglioma, the
patient was started on α adrenergic blockade. Cystoscopic
examination under spinal anesthesia showed a small exo-
phytic yellowish submucosal mass in the left anterior wall
near the bladder neck. Histological analysis revealed a
highly vascular neoplasm covered by normal urothelium.
Tumor cells were backed into small nests surrounded by a
ﬁbrovascular network. The cytoplasm was eosinophilic with
indistinct borders (Figure 2). Immunostains were positive
for chromogranin A, neurone-speciﬁc enolase, S-100 protein
and sinaptophysin, while immunostains for epithelial dif-
ferentiation (using antikeratin monoclonal antibody) were
negative (Figure 3). These ﬁndings were consistent with
paraganglioma of the bladder. There was no change in blood
pressure during cystoscopy or during manipulation of the
tumor. Partial cystectomy was carried out with uneventful
postoperative course. The surgical margin of the removed
specimen was negative.2 Advances in Urology
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Figure 1: Axial CT scan of the pelvis after IV contrast: oval shape
well-deﬁned homogenous small mass at the bladder neck which
shows intense enhancement after contrast.
Postoperative hormone levels, including plasma meta-
nephrines, and urinary VMA, were normal. Iodine-131-m–
iodobenzylguanidine (131I-MIBG) scintigraphy and abdom-
inal CT scan 12 months after the procedure showed no
recurrence.
3. Discussion
Bladder pheochromocytoma occurs more frequently in
women than in men, and mainly during the third decade
of life [3]. The tumor is usually benign, only 15–20%
beingmalignant[4].Thepresenting symptomsusuallyresult
from excessive catecholamine secretion. The patient typically
suﬀers from hypertensive crises that may be accompanied
by headache, palpitations, hot ﬂushes, and sweating. These
crises are mainly provoked by micturition, overdistention
of the bladder, defecation, sexual activity, ejaculation, or
bladder instrumentation. Haematuria is the presenting com-
plaint in about 60% of reported cases. It has been estimated
that only 17% of bladder pheochromocytomas patient are
hormonally nonfunctional (paraganglioma) [5].
At present, the best imaging method to detect and fol-
low patients with paragangliomas is uncertain. Anatomical
imaging with CT scan and MRI can usually detect most of
these lesions. MRI using various sequences has been proven
to be superior to CT scan [1]. In addition, intravenous
contrast of the CT scan can provoke the catecholamine
release [6]. Functional imaging that speciﬁcally targets the
catecholamine synthesis, storage, and secretion pathway
is helpful in patients with paraganglioma especially after
surgical removal or in detection of metastasis. These imag-
ing modalities include 123I-MIBG, 18F-FDA, 18F-FDOPA,
18F-FDG,11C-epinephrine, and 11C-hydroxyephedrine. 123I-
MIBG is preferred over 131I-MIBG because of higher sen-
sitivity, lower radiation exposure, and improved imaging
quality [7]. Timmers et al. reported 97% sensitivity of 18F-
FDG in patients with metastatic paraganglioma [8]. One of
the drawbacks of the functional studies is that the materials
tend to accumulate in the bladder and hide the bladder
lesion. Some reports had recommended bladder irrigation to
delineate the bladder lesion [9].
Figure 2: The tumor cells show the characteristic zellballen cells,
with abundant eosinophilic cytoplasm and an ill-deﬁned wall
separated by ﬁbrovascular stroma. Mitotic ﬁgures are not observed.
Hematoxylin-Eosin Stain (X400).
Figure 3: Immunostaining for chromogranin A showed strong and
diﬀuse positivity in the tumor cell cytoplasm (X400).
The patient had his ﬁrst paraganglioma removed at age
of 29 which raise the suspicion of familial form of the
disease. Recent data have suggested that between 25%–30%
of these tumors might be familial in nature [10]. Germline
mutations in NF1, ret, VHL, SHDB, SDHC, and SDHD had
been associated with paraganglioma [11]. Korpershoek et al.
recommendedgenetictestingforpatientswithextra-adrenal,
bilateral, or multiple pheochromocytomas regardless of age,
because it is known that such presentations frequently occur
in the context of a heritable tumor syndrome [11].
Assessments of plasma and/or urine catecholamine
levels are very important in these patients even if they
are asymptomatic. It is crucial in the initial assessment
and in the follow up afterward. Lenders et al. reported
that plasma metanephrines are more sensitive and speciﬁc
than urinary metanephrines for these lesions [12]. On the
other hand, we should be aware that medications, includ-
ing tricyclic antidepressants, decongestants, amphetamines,
antipsychotic medications, reserpine, levodopa, ethanol,
and acetaminophen, can increase both urine and plasma
catecholamine measurements and cause false positive tests
[13].
Cystoscopic appearance of a yellow, submucosal tumor
should raise the suspicion of a bladder pheochromocytoma.Advances in Urology 3
Precautions should be taken to avoid potentially lethal
transient hypertensive crises during tumor manipulation.
Preoperative alpha blockade is used to counteract the eﬀects
oftheelevatedcatecholaminesduringsurgicalmanipulation.
Before tumor removal, beta blockers can be initiated to
protect against cardiovascular abnormalities like tachycardia
or arrhythmias.
Treatment of bladder paraganglioma requires total exci-
sion of the tumor by partial cystectomy. Transurethral
resection is usually inadequate because the majority of
tumors extend in the deep layers of the detrusor muscle.
Total cystectomy is reserved for large lesions when bladder
preservation is impossible or in the presence of lymph
node metastasis. Pelvic lymph node dissection has been
recommended in order to exclude metastatic disease in
all cases of bladder paraganglioma [5]. The prediction
of the biological behavior of a bladder paraganglioma
cannot be based solely on the histopathological ﬁndings.
Some criteria have evolved to suggest malignancy behavior
which includes necrosis, angiolymphatic invasion, high
mitotic index, absence of hyaline bodies, p53 alteration,
and DNA ploidy analysis. However the diagnosis of a
malignant tumor is diﬃcult and is often proved clinically
through presence of metastases [4]. Recurrence of the
disease at the site of resection should not be considered
as evidence of malignancy [14]. Bladder paraganglioma is
a chemo-resistant and radio-resistant tumor, though such
regimens were used in inoperable cases with relative eﬃcacy
[15].
Life-long follow-upis necessary todetectlate recurrences
[14]. Follow up should be regular and include cystoscopic
examination, plasma or urinary catecholamines levels and
imaging study (CT scan and 123I-MIBG scintiscan). There
is no consensus about the frequency of these measures;
however, we suggested that there should be at least an annual
follow-up for these patients if they are asymptomatic or
whenever clinically indicated.
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